TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28288682

Group type: EXPERIMENTAL
Intervention: ADA continuation (n=61)
Number of subjects: 135

Group type: COMPARATOR
Intervention: ADA discontinuation (n=74)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Initial intensive therapy (ADA + MTX)
Number of subjects: 135

Group type: COMPARATOR
Intervention: ADA discontinuation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: ADA continuation
Number of subjects: 135
Study: 28288747

Group type: EXPERIMENTAL
Intervention: SMS only
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: SMS plus 75 KES
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: SMS plus 200 KES
Number of subjects: 2018

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2018

Group type: EXPERIMENTAL
Intervention: SMS plus 200 KES vs Control
Number of subjects: 2018
Study: 28288963

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR) defined as P2Y12 reaction units >208
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease (PAD)
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 8582

Group type: EXPERIMENTAL
Intervention: Patients with both PAD and HPR
Number of subjects: 8582

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 8582
Study: 28289008

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28289025

Group type: EXPERIMENTAL
Intervention: Low-dose primaquine
Number of subjects: 0
Study: 28289046

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for fertility preservation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative evaluation of PtDA usage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 0
Study: 28289215

Group type: EXPERIMENTAL
Intervention: Dietary supplement kit consisting of monoamine precursor amino acids and dietary antioxidants (including tryptophan and tyrosine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 41
Study: 28289402

Group type: EXPERIMENTAL
Intervention: Pasireotide SC injection
Number of subjects: 6
Study: 28290120

Group type: EXPERIMENTAL
Intervention: Intravenous clindamycin dosing of 9 mg/kg/dose for children ≤5 months, 12 mg/kg/dose for children >5 months-6 years, and 10 mg/kg/dose for children 6-18 years, administered every 8 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal dosing proposed by the pediatric PBPK model.
Number of subjects: 0
Study: 28290744

Group type: EXPERIMENTAL
Intervention: Targeted MVPA-focused intervention for students with elevated impulsiveness and cognitive dissonance
Number of subjects: 333
Study: 28291376

Group type: EXPERIMENTAL
Intervention: Cardioversion of atrial fibrillation to sinus rhythm
Number of subjects: 23
Study: 28291584

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for up to 2 years)
Number of subjects: 25
Study: 28291640

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (initial dose 450 μg subcutaneously once per week, reduced to 90 mg per week)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Number of subjects: 83
Study: 28291870

Group type: EXPERIMENTAL
Intervention: Evolocumab, 420 mg plus standard of care (SOC)
Number of subjects: 1324

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Evolocumab, 420 mg plus SOC
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Evolocumab treatment
Number of subjects: 1324
Study: 28292280

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia patients
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Non-diseased persons
Number of subjects: 1707
Study: 28292290

Group type: EXPERIMENTAL
Intervention: Direct reduction (DR) technique through posterolateral approach
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Direct reduction (DR) technique
Number of subjects: 116

Group type: COMPARATOR
Intervention: Indirect reduction (IR) technique using ligamentotaxis
Number of subjects: 116
Study: 28292858

Group type: EXPERIMENTAL
Intervention: Age-sex percentiles of segment involvement score (SIS)
Number of subjects: 21132

Group type: COMPARATOR
Intervention: SIS% groups (≤50th, 51-75th, >75th)
Number of subjects: 21132
Study: 28292941

Group type: EXPERIMENTAL
Intervention: BAY 1129980 (C4.4A-ADC), an antibody-drug conjugate targeting C4.4A
Number of subjects: 0
Study: 28292947

Group type: EXPERIMENTAL
Intervention: Intravenous plerixafor at a dose of 0.32 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous plerixafor (not specified in detail)
Number of subjects: 0
Study: 28293022

Group type: EXPERIMENTAL
Intervention: Response-adapted consolidation with bortezomib after ASCT
Number of subjects: 0
Study: 28293270

Group type: EXPERIMENTAL
Intervention: Moringa (1.85 g leaf powder/day)
Number of subjects: 11
Study: 28293280

Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 28293424

Group type: EXPERIMENTAL
Intervention: SCAD (Smoothly Clipped Absolute Deviation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive LASSO (Least Absolute Shrinkage and Selection Operator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MCP (Minimax Concave Penalty)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional stepwise regression method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammation markers (Myeloperoxidase (MPO) at week 12 and soluble CD14 at week 18)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mother weight and height-for-age z-score (HAZ) at week 18
Number of subjects: 0
Study: 28293431

Group type: EXPERIMENTAL
Intervention: Text messages plus phone call reminders
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phone call reminders only (usual care)
Number of subjects: 40
Study: 28295849

Group type: EXPERIMENTAL
Intervention: simeprevir (SMV), daclatasvir (DCV), and ribavirin (RBV) for 24 weeks
Number of subjects: 35
Study: 28296283

Group type: EXPERIMENTAL
Intervention: Transendocardial CD34 treatment, details on dosage and duration not provided
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28296993

Group type: EXPERIMENTAL
Intervention: Cellulitis
Number of subjects: 54
Study: 28297015

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy
Number of subjects: 11648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11648
Study: 28298048

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of physical strain within carotid atherosclerotic plaques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of microemboli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White matter hyperintensity
Number of subjects: 0
Study: 28298401

Group type: EXPERIMENTAL
Intervention: Surgery after radiation therapy (SMART)
Number of subjects: 65
Study: 28298402

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 13
Study: 28298405

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28298564

Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nilotinib treatment (control group for signature validation)
Number of subjects: 0
Study: 28299283

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg daily until disease progression or unacceptable toxicity
Number of subjects: 17
Study: 28300867

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 28301073

Group type: EXPERIMENTAL
Intervention: In-center hemodialysis (6 d/wk)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis (6 nights/wk)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional thrice-weekly hemodialysis
Number of subjects: 195
Study: 28302081

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Questionnaire for Physical Therapists (MSQPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAQUAMS (control)
Number of subjects: 0
Study: 28302090

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Chemotherapy-alone regimens
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Overall response rates
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: CLL-related deaths in LOT1
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: CLL-related deaths in LOT≥2
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Infection-related deaths in LOT1
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Infection-related deaths in LOT≥2
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Prognostic score for E-CLL patients
Number of subjects: 455
Study: 28302137

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) followed by two cycles of R (R-CHOP-14)
Number of subjects: 76
Study: 28303154

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified; control group not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified; ongoing studies include MSCs therapy in emphysema and several studies of ADSCs in COPD.
Number of subjects: 0
Study: 28304217

Group type: EXPERIMENTAL
Intervention: Teriflunomide (oral immunomodulator, once-daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study: 28306749

Group type: EXPERIMENTAL
Intervention: Smoking (smokers, n = 277)
Number of subjects: 931

Group type: COMPARATOR
Intervention: Non-smoking (non-smokers, n = 654)
Number of subjects: 931
Study: 28314691

Group type: EXPERIMENTAL
Intervention: Dexamethasone mouthwash (10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL oral solution, swish for 2 min and spit, four times daily for 8 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Historical controls from the BOLERO-2 trial (everolimus and exemestane treatment without dexamethasone mouthwash)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Dexamethasone mouthwash
Number of subjects: 92
Study: 28314699

Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice a day, Lenalidomide 15 mg on days 1-21 in a 28-day cycle, Rituximab 375 mg/m2 (initially included)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Idelalisib 150 mg twice a day, Lenalidomide 15 mg on days 1-21 in a 28-day cycle
Number of subjects: 11
Study: 28314711

Group type: EXPERIMENTAL
Intervention: HERDOO2 rule
Number of subjects: 0
Study: 28314788

Group type: EXPERIMENTAL
Intervention: Veliparib added to Bendamustine and Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine and Rituximab alone
Number of subjects: 0
Study: 28314833

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 277

Group type: COMPARATOR
Intervention: No Diabetes Mellitus
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Intima-Media Thickness
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Dilatation of Retinal Veins in Response to Flicker Light
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Creatinine Levels
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Venous Dilatation in Response to Flicker Light
Number of subjects: 277
Study: 28314862

Group type: EXPERIMENTAL
Intervention: mTBI cases
Number of subjects: 557

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 557
Study: 28315940

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including low tidal volume (≤7 ml/kg), moderate PEEP (6-8 cm H2O), and early extubation.
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Compliance with recommendations (n=60, 8% of patients).
Number of subjects: 744
Study: 28317031

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28318045

Group type: EXPERIMENTAL
Intervention: Adding epithelial hyperplasia as a criterion
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Symptom-based GERD diagnosis without epigastric pain
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 231
Study: 28318100

Group type: EXPERIMENTAL
Intervention: Heat-treated blood at 45 °C for 15 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heat-treated material
Number of subjects: 6
Study: 28318636

Group type: EXPERIMENTAL
Intervention: Peripheral Laser Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 0
Study: 28319446

Group type: EXPERIMENTAL
Intervention: Transduced UCB CD34+ cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mock-transduced UCB CD34+ cells
Number of subjects: 20
Study: 28319597

Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 57
Study: 28320214

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients
Number of subjects: 32
Study: 28320242

Group type: EXPERIMENTAL
Intervention: Early, goal-directed therapy (EGDT)
Number of subjects: 3723

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3723
Study: 28320361

Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: RSV
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: High-risk status
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Influenza B
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: RSV hospitalizations
Number of subjects: 500000
Study: 28320486

Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy with the left jackknife position
Number of subjects: 10
Study: 28320707

Group type: COMPARATOR
Intervention: Procedures in lower volume centers (200-399 PCI cases per year)
Number of subjects: 427467

Group type: COMPARATOR
Intervention: Procedures in higher volume centers (1500-1999 PCI cases per year)
Number of subjects: 427467

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 427467

Group type: EXPERIMENTAL
Intervention: Overall PCI cohort
Number of subjects: 427467
Study: 28320791

Group type: COMPARATOR
Intervention: No to mild PLE
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate to severe PLE
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reduction of PLE (follow-up)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: NYHA-class (follow-up)
Number of subjects: 62
Study: 28320796

Group type: EXPERIMENTAL
Intervention: Hazardous alcohol consumption (Alcohol Use Disorders Identification Test-C score ≥3)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Low alcohol intake
Number of subjects: 571

Group type: COMPARATOR
Intervention: Depressive symptoms, non-specific psychological distress, physical and psychological IPV
Number of subjects: 571

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 571
Study: 28321002

Group type: EXPERIMENTAL
Intervention: Transfemoral approach (TF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transapical approach (TA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mild or greater aortic regurgitation (AR) at 1 week
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High STS score (>8)
Number of subjects: 64
Study: 28321003

Group type: EXPERIMENTAL
Intervention: TAVI with the CoreValve System (26-mm/29-mm cohort)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TAVI with the CoreValve System (23-mm cohort)
Number of subjects: 75
Study: 28321004

Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 30
Study: 28322082

Group type: EXPERIMENTAL
Intervention: Second-generation PET radioligands for TSPO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prototypical PET radioligand for TSPO
Number of subjects: 0
Study: 28322812

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 28323236

Group type: EXPERIMENTAL
Intervention: Tailored ventilator regimens based on lung morphology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume-controlled ventilation with low tidal-volumes (Vt) targeting a plateau pressure ≤30 cmH2O
Number of subjects: 0
Study: 28323923

Group type: EXPERIMENTAL
Intervention: Genetic variation affecting FSH production (FSHB c.-211G>T)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Ligand-receptor variant combination resulting in weak FSH action
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: BMI z score
Number of subjects: 1554
Study: 28323951

Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) study
Number of subjects: 28

Group type: COMPARATOR
Intervention: Common prediction equations for TDEE
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hyperinsulinemia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hyperandrogenemia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Equation derived from DLW
Number of subjects: 28
Study: 28323960

Group type: EXPERIMENTAL
Intervention: Intact FGF23
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum phosphate and renal phosphate excretion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: C-terminal FGF23
Number of subjects: 90
Study: 28323970

Group type: EXPERIMENTAL
Intervention: Oocyte gene expression in OW women
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Serum and FF hormone and lipid levels in OW women
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Body composition metrics in OW women
Number of subjects: 24
Study: 28323999

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese men
Number of subjects: 6238

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese women
Number of subjects: 6238

Group type: EXPERIMENTAL
Intervention: Metabolically healthy overweight men
Number of subjects: 6238

Group type: EXPERIMENTAL
Intervention: Metabolically healthy overweight women
Number of subjects: 6238
Study: 28324009

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Simulated WES data
Number of subjects: 27
Study: 28324018

Group type: EXPERIMENTAL
Intervention: Highest TSH tertile (2.14 to 86.7 mIU/L)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Lowest TSH tertile (<1.28 mIU/L)
Number of subjects: 541
Study: 28324042

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg)
Number of subjects: 73
Study: 28324110

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.04 to 0.19 mg/kg/d)
Number of subjects: 53
Study: 28324749

Group type: EXPERIMENTAL
Intervention: SAR405838 400 mg QD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SAR405838 300 mg QD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SAR405838 weekly schedule
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SAR405838 1800 mg twice weekly
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SAR405838
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SAR405838 in de-differentiated liposarcoma MTD cohort
Number of subjects: 74
Study: 28324891

Group type: EXPERIMENTAL
Intervention: MSKCC nomogram and Tenon score (low risk: ⩽10% probability of metastatic non-SN and Tenon score ⩽3.5)
Number of subjects: 2822

Group type: COMPARATOR
Intervention: High risk group (not specified intervention)
Number of subjects: 2822
Study: 28325399

Group type: EXPERIMENTAL
Intervention: Hedgehog pathway inhibitor therapy
Number of subjects: 0
Study: 28325769

Group type: EXPERIMENTAL
Intervention: Neuraminidase antibody responses measured by ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibition assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibodies binding to the conserved stalk domain of hemagglutinin
Number of subjects: 0
Study: 28325785

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (specific details not available)
Number of subjects: 0
Study: 28325783

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibition (chronic, 4 weeks)
Number of subjects: 66
Study: 28325857

Group type: EXPERIMENTAL
Intervention: Laser treatment, cryotherapy, vascular endothelial growth factor (VEGF) inhibitor, vitrectomy/scleral buckling, or a combination thereof.
Number of subjects: 327
Study: 28326189

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + csDMARDs
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + csDMARDs
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Sarilumab + csDMARDs
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo + csDMARDs
Number of subjects: 546
Study: 28326509

Group type: EXPERIMENTAL
Intervention: Immunoassays (IAs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Liquid-chromatography tandem mass-spectrometry (LC-MS/MS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both IAs and LC-MS/MS after hCG stimulation
Number of subjects: 27
Study: 28326839

Group type: EXPERIMENTAL
Intervention: Entinostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane + Entinostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemestane + Placebo
Number of subjects: 0
Study: 28326849

Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII (rFVIII)
Number of subjects: 183
Study: 28327100

Group type: EXPERIMENTAL
Intervention: CME-M (Continuing Medical Education meeting)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Non-participating reference practices
Number of subjects: 396
Study: 28327104

Group type: EXPERIMENTAL
Intervention: Functional principal component analysis (FPCA) for modeling height-for-age z-scores (HAZ) over the first 24 months of life.
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Adj-FPC2 score derived from FPCA.
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Risk factors associated with growth faltering identified through linear regression.
Number of subjects: 626
Study: 28327200

Group type: EXPERIMENTAL
Intervention: LY2787106 (0.3-10 mg/kg every 3 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LY2787106 (10 mg/kg weekly)
Number of subjects: 33
Study: 28327462

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects on cART
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45